Inhibitors in Thyroid Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (5 September 2023) | Viewed by 276
Special Issue Editor
Interests: cancer; immunotherapies; immune checkpoint inhibitors; ipilimumab; nivolumab; thyroid cancer; papillary thyroid cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The aim of this Special Issue will be to review and discuss new advancements in the therapy of aggressive iodine refractory thyroid carcinoma (RAI-TC). The most common altered signaling found in aggressive RAI-TC are RTK, MAPK, PI3K, WNT, BRAF, RAS, RET, and TP53. Sorafenib and lenvatinib are tyrosine kinase inhibitors (TKI) that have recently been approved for the treatment of RAI-TC. These drugs are able to elicit an anti-neoplastic activity by acting against different pathways. Other studies are evaluating vandetanib and selumetinib in RAI-TC, as well as dabrafenib, and vemurafenib in BRAF mutated RAI-TC patients to re-induce 131-iodine uptake. Different mechanisms of resistance to TKIs inhibitors can occur, for example, an acquired resistance to lenvatinib or sorafenib can be due to the upregulation of FGFR; therefore, anti-FGFR agents are evaluated. Additionally, knowing the genetic signature of the cancer is very important in order to choose the right treatment avoiding the administration of inefficacious drugs, and also to explore new ways to fight the tumor. A new investigating field is about the interplay between cells of the immune system and cancer cells. The expression of PDL1 in RAI-TC has been related to tumor recurrence and poor survival. Therefore, several clinical trials are investigating a combination of different therapies, such as lenvatinib and pembrolizumab, and immune-checkpoint inhibitors. The abovementioned arguments will be addressed in the Special Issue.
Prof. Dr. Alessandro Antonelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thyroid carcinoma
- immune checkpoints inhibitors
- tyrosine kinase inhibitors
- sorafenib
- lenvatinib
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
